troglitazone has been researched along with Papilloma in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Papilloma: A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thuillier, P | 1 |
| Anchiraico, GJ | 1 |
| Nickel, KP | 1 |
| Maldve, RE | 1 |
| Gimenez-Conti, I | 1 |
| Muga, SJ | 1 |
| Liu, KL | 1 |
| Fischer, SM | 1 |
| Belury, MA | 1 |
1 other study available for troglitazone and Papilloma
| Article | Year |
|---|---|
Activators of peroxisome proliferator-activated receptor-alpha partially inhibit mouse skin tumor promotion.
Topics: Animals; Anticarcinogenic Agents; Bezafibrate; Blotting, Western; Cell Differentiation; Cell Line; C | 2000 |